Recent scientific developments in medicine have the potential to cure or fundamentally modify previously incurable or poorly treated diseases and conditions, relieving the suffering of patients and ...

Regardless of the outcome of the current health reform debate, patients are likely to continue to be asked to take more responsibility for their health care, whether through high-deductible health ...

BOSTON, MA - JUNE 6, 2019: Steven Pearson, President of the Institute for Clinical and Economic Review (ICER), talks with chief medical officer David Rind during a meeting at their offices in Boston. ...

Much of the biopharmaceutical industry this week is focused on the J.P. Morgan Healthcare Conference (JPM), where business leaders are investing in science and technologies with the potential to ...

Laying a clear path for incorporating reliable evidence on heterogeneity in value assessments could improve their applicability for healthcare decision making. The ICER perspective on what value means ...

Trying to gauge the value of new drugs and devices is becoming increasingly important in the U.S. health care system, something that other countries have done explicitly for years. Pressure to get ...